Fangyuan Xing1, Yongrong Liu2, Ruifang Dong1, Ye Cheng1. 1. Department of Neurology, Cangzhou Central Hospital, No. 16 Xinhua West Road, Cangzhou, Hebei 061000, People's Republic of China. 2. Department of Ultrasound, Cangzhou Central Hospital, No. 16 Xinhua West Road, Cangzhou, Hebei 061000, People's Republic of China.
Abstract
To date, studies have demonstrated the potential functions of microRNAs in cerebral ischemia reperfusion (IR) injury. Herein, we established a middle cerebral artery occlusion (MCAO) model in rats and then subjected them to reperfusion to explore the role of microRNA-374 (miR-374) in cerebral IR injury. After reperfusion, the endogenous miR-374 level decreased, and the expression of its target gene, Wnt5a, increased in brain tissues. Intracerebral pretreatment of miR-374 agomir attenuated cerebral damage induced by IR, including neurobehavioral deficits, infarction, cerebral edema and blood-brain barrier disruption. Moreover, rats pretreated with miR-374 agomir showed a remarkable decrease in apoptotic neurons, which was further confirmed by reduced BAX expression as well as increased BCL-2 and BCL-XL expression. A dual-luciferase reporter assay substantiated that Wnt5a was the target gene of miR-374. miR-374 might protect against brain injury by downregulating Wnt5a in rats after IR. Thus, our study provided a novel mechanism of cerebral IR injury from the perspective of miRNA regulation.
To date, studies have demonstrated the potential functions of microRNAs in cerebral ischemia reperfusion (IR) injury. Herein, we established a middle cerebral artery occlusion (MCAO) model in rats and then subjected them to reperfusion to explore the role of microRNA-374 (miR-374) in cerebral IR injury. After reperfusion, the endogenous miR-374 level decreased, and the expression of its target gene, Wnt5a, increased in brain tissues. Intracerebral pretreatment of miR-374agomir attenuated cerebral damage induced by IR, including neurobehavioral deficits, infarction, cerebral edema and blood-brain barrier disruption. Moreover, rats pretreated with miR-374 agomir showed a remarkable decrease in apoptotic neurons, which was further confirmed by reduced BAX expression as well as increased BCL-2 and BCL-XL expression. A dual-luciferase reporter assay substantiated that Wnt5a was the target gene of miR-374. miR-374 might protect against brain injury by downregulating Wnt5a in rats after IR. Thus, our study provided a novel mechanism of cerebral IR injury from the perspective of miRNA regulation.
Ischemic stroke, also known as ischemic cerebrovascular disease (ICVD) and cerebral
infarction, is a kind of disease involving brain tissue necrosis that caused by stenosis or
occlusion of a cerebral blood supply artery and insufficient blood supply to the brain.
Ischemic stroke is one of the leading causes of mortality and serious long-term disability,
making it the most common life-threatening neurological disease [1]. About 15 million patients suffer an ischemic stroke each year
globally, resulting in death in over 5 million of the patients and permanent disability in
another 5 million [2]. Moreover, the incidence of
recurrent ischemic stroke is 11.3% after 5 years [3].
Problems such as motor dysfunction after an ischemic stroke and recurrence seriously
affected the quality of life of patients. Although restoration of the blood supply through
reperfusion can improve clinical outcomes, rapid reperfusion may also result in the
exacerbation of cerebral injury [4]. Cerebral ischemia
reperfusion (IR) injury has become an increasingly tough challenge for strokepatients.
Therefore, efforts to further study effective prevention and management in ischemic stroke
are urgently needed.MicroRNAs (miRNAs) are a class of small non-coding RNAs that play important roles in
cerebral IR injury by regulating the expression of target genes [5, 6]. For example, miR-106b-5p
ameliorates cerebral IR injury by inhibiting apoptosis and oxidative stress [7]. mir-431 exerts protective effects against cerebral IR
injury by targeting the Rho/Rho-kinase signaling pathway [8]. Recent evidence suggests that supplementation with miR-7 mimics may be a
therapeutic option to minimize stroke-induced brain damage and disability [9]. miR-374 was previously found to display an increasing
expression level in an embolic stroke model [10] and
was later discovered to protect against myocardial IR injury in adult rodents. Zhang
et al. demonstrated that miR-374 mitigated ratmyocardial IR injury by
targeting SP1 through the activation of the PI3K/Akt signal pathway after pretreatment with
sevoflurane [11]. Another study conducted by Zhao
et al. showed that miR-374 alleviated myocardial IR injury in mice after
thoracic epidural anesthesia by suppressing the activity of a DTNA-mediated Notch1 axis
[12]. The above studies revealed that miR-374 might
be a therapeutic target for IR injury, but all of them focused on the myocardium; its effect
on cerebral IR injury is far from being elucidated, and the underlying mechanism also needs
to be further studied.Wnt5a is a signaling molecule belonging to the large Wnt family. As an extracellular ligand
of the Wnt noncanonical pathway, it regulates the β-catenin-independent pathway by binding
to plasma membrane receptors or co-receptor complexes and activating Dishevelled (Dvl)
phosphoproteins in the cytoplasm [13], which
modulates various cellular functions, including migration, adhesion, invasion, metastasis,
and differentiation [14,15,16,17]. It is well known that abnormalities of Wnt5a signaling are involved
in several human diseases, such as cancers, inflammatory diseases, and metabolic disorders
[18,19,20,21]. Previous
evidence suggested that noncanonical Wnt5a/JNK signaling was implicated in cardiac injury
under ischemic stress, and this signaling was suppressed by Sfrp5, thereby protecting the
heart from IR injury [22]. Furthermore, Wnt5a has
been reported to play a crucial role in stroke. Both in vitro and
in vivo studies have shown that inhibition of Wnt5a could alleviate
cerebral IR injury, which provided a novel target for stroke therapy [23].Given that Wnt5a is a target gene of miR-374 (predicted with TargetScan
and the Starbase database), we hypothesized that miR-374 may regulate cerebral IR injury
through targeting of Wnt5a. Therefore, our study investigated the role of
miR-374 in brain IR injury and neuronal apoptosis in a rat model of cerebral IR and whether
it was associated with its targeting of Wnt5a.
Materials and Methods
Animals and grouping
Adult male Sprague-Dawley rats (weighing 230–250 g) were purchased from Changsheng
Biotechnology (Liaoning, China) and maintained under optimal conditions (25 ± 1°C, 45–55%
humidity, and a 12 h light/dark cycle). All animal experiments were approved by the animal
research ethics committee of Cangzhou Central Hospital and performed in accordance with
the Guide for Laboratory Animal Care and Use. The animal experiment consisted of three
parts. For the first part, the rats were randomly assigned to two groups, with 6 rats in
each group: the sham and IR groups. For the second part, the rats were randomly assigned
to five groups, with 6 rats in each group: the control, sham 6 h, IR 6 h, IR 24 h, and IR
72 h groups. For the third part, the rats were randomly assigned to four groups, with 36
rats in each group: the sham, IR, IR + NC agomir, IR 24 h + miR-374 agomir groups. After
the experiment, the rats were sacrificed by CO2 inhalation. The rats from each
group were then randomly assigned for different determinations: six rats in each group
were used for the determination of neurobehavioral score, six rats in each group were used
for the evaluation of infarct volume, six rats in each group were used for real-time PCR
and Western blot analyses, six rats in each group were used for the evaluation of brain
water content, six rats in each group were used for the measurement of blood-brain barrier
leakage by Evans, and six rats in each group were used for immunofluorescence
staining.
Establishment of rat models of cerebral IR injury
Anesthesia was induced with 1% pentobarbital (40 mg/kg, i.p.). After midline neck
incision, the right common carotid artery (CCA), internal carotid artery (ICA), and
external carotid artery (ECA) were exposed and isolated. The CCA and ECA were then ligated
with 3–0 monofilament respectively. A polylysine-coated nylon filament was employed as an
embolus and inserted into the ICA through the ECA stump to occlude the middle cerebral
artery. The filament was pushed through the carotid bifurcation and 18–22 mm into the ICA,
stopping when there was slight resistance. After 120 min of ischemia, the rat models of
middle cerebral artery occlusion (MCAO) was established, and the nylon filament was then
withdrawn for 24 h of reperfusion. In the sham procedure, rats were treated identically
without occlusion of the middle cerebral artery.
Intracerebroventricular pretreatment
Rats were injected intracerebrally 2 h before MCAO. They were anesthetized with
pentobarbital and placed in a stereotaxic frame. A puncture needle was implanted
stereotaxically into the infarct side ventricle (bregma, posterior 0.8 mm; median line,
right 1.5 mm; bone surface, downwards 4.5 mm). miR-374 agomir or negative control agomir
(3 pmol/g body weight in 2 µl) was mixed with cationic lipidDOTAP (4
µl, 6 µl total volume) and was injected via
microinfusion pump (0.5 µl/min). Agomir is a specially labeled and
chemically modified double-stranded small RNA that mimics the endogenous miRNA to regulate
the biological function of target genes. The sequences of miR-374 agomir and NC agomir are
as follows: 5’-AUAUAAUACAACCUGCUAAGUG-3’ (sense) and 5’-CUUAGCAGGUUGUAUUAUAUUU-3’
(antisense) for miR-374 agomir and 5’-UUCUCCGAACGUGUCACGUTT-3’ (sense) and
5’-ACGUGACACGUUCGGAGAATT-3’ (antisense) for NC agomir.
Neurobehavioral score
The neurobehavioral scores of rats were determined after 24 h of reperfusion. The scoring
system was composed with motor tests, sensory tests, beam balance tests, and tests for
reflex absence and abnormal movements. Neurological function was scored on a scale of 0 to
18 (0, normal score; 18, maximal deficit score). The procedures performed in the above
tests were described in a previous study [24]. In
injury severity scoring, one point is awarded for inability to perform a task or for the
lack of a tested reflex; the higher the score, the more serious the injury.
Infarct volume
After sacrifice, brains were removed, frozen at −20°C for 30 min to fix the brain
tissues, and cut into 2 mm slices. Slices were incubated in 1% 2,3,5-triphenyltetrazolium
chloride (TTC) for 15 min at 37°C. Images of brain sections were recorded. The infarct
volume was calculated using the ImageJ software and was determined by infarction rate (%)
= the infarct volume / the volume of the homolateral hemisphere ×100.
Real-time PCR
An RNAsimple Total RNA Kit (DP419, Tiangen Biotech, Beijing, China) was used to extract
total RNA from brain tissues. Briefly, tissues were added with 1 ml Buffer RZ and
homogenized. The homogenized samples were incubated at room temperature for 5 min. After
centrifuging at 10,000 g for 10 min at 4°C, the colorless upper aqueous phase (containing
RNA) was pipetted into a new tube. Then 0.5 volumes of ethanol was added to the aqueous
phase and mixed thoroughly. The sample was transferred to an RNase-Free spin column CR3
placed in an RNase-Free collection tube. After centrifuging at 10,000 g for 30 s at 4°C,
the flow-through was discarded. Then, Buffer RD (500 µl) was added to the
spin column CR3. After centrifuging at 10,000 g for 30 s at 4°C, the flow-through was
discarded, and then 500 µl Buffer RW was added to the spin column CR3.
After incubating at room temperature for 2 min and centrifuging at 10,000 g for 30 s at
4°C, the flow-through was discarded; this step was repeated after adding 500
µl Buffer RW to the spin column CR3. The spin column CR3 was set back
in the collection tube and centrifuged at 10,000 g for 2 min at 4°C. It was then placed in
a new RNase-Free collection tube. After adding 30–100 µl RNase-Free
ddH2O, the column was incubated at room temperature for 2 min. RNA was eluted
after centrifugation at 10,000 g or 2 min at 4°C, and the concentration was determined.
RNA was reverse transcribed with M-MLV Reverse Transcriptase (NG212, Tiangen Biotech).
Real-time PCR reactions were conducted with SYBR Green (SY1020, Solarbio, Beijing, China)
and 2 × Taq PCR MasterMix (KT201, Tiangen Biotech). The primers used were as follows:
5’-ACAGCCGCTTCAACTCCCCAACC-3’, forward, and 5’-TCGCAGCCGTCCATCCCCTCT-3’, reverse, for
Wnt5a; 5’-CGGCAAGTTCAACGGCACAG-3’, forward, and
5’-CGCCAGTAGACTCCACGACAT-3’, reverse, for Gapdh;
5’-GTTGGCTCTGGTGCAGGGTCCGAGGTATTCGCACCAGAGCCAACCACTTA-3’, RT primer,
5’-ATATAATACAACCTGCTAAGTG-3’, forward, and 5’-GCAGGGTCCGAGGTATTC-3’, reverse, for
rno-miR-374-5p; and 5’-GTTGGCTCTGGTGCAGGGTCCGAGGTATTCGCACCAGAGCCAACAAAGCCTAC-3’, RT
primer, 5’-GATCTCGGAAGCTAAGCAGG-3’, forward, and 5’-TGGTGCAGGGTCCGAGGTAT-3’ reverse, for
5s. Measurements for mRNA were normalized to Gapdh, and rno-miR-374-5p
was normalized to 5s. The relative expression was obtained using the 2−ΔΔCt
method.
Western blot analysis
Brain tissues were collected and lysed with RIPA lysis buffer (R0010, Solarbio) plus
phenylmethylsulfonyl fluoride (P0100, Solarbio). A BCA Protein Assay Kit (PC0020,
Solarbio) was used to measure protein concentrations. After separation with 8–15% sodium
dodecyl sulfate-polyacrylamide gel, the proteins were transferred to PVDF membranes. Then
the membranes were blocked with 5% non-fat milk and incubated with primary antibodies and
corresponding secondary antibodies (Solarbio). The protein bands were visualized with an
enhanced chemiluminescence reagent (PE0010, Solarbio). The primary antibodies were as
follows: Wnt5a antibody (DF6856, Affinity, Cincinnati, OH, USA), Bcl-xl antibody (AF6414,
Affinity), Bcl-2 antibody (AF6139, Affinity), Bax antibody (AF0120, Affinity), GAPDH
antibody (60004-1-Ig, Proteintech, Wuhan, China).
Measurement of brain water content
After 24 h of reperfusion, rats were sacrificed, and their brains were removed. The fresh
brain tissues from the ischemic hemisphere were weighed to obtain the wet weight and then
dried in an oven at 100°C for 24 h to obtain the dry weight. The brain water content (%)
was calculated as follows: (wet weight − dry weight) / wet weight × 100.
Evans blue injection and brain extraction
The blood-brain barrier (BBB) leakage was measured by Evans blue (EB) staining as
described previously [25]. Briefly, rats were
subjected to tail vein injection with 2% Evans blue (2 ml/kg), and sacrificed 1 h after
the injection. After thoracotomy, perfusion with normal saline through the left ventricle
was performed to wash away any remaining dye within the blood vessels. The ischemic
hemisphere was removed and weighed to determine the wet weight. Evans blue was extracted
by adding 1 ml formamide to 100 mg of tissue, followed by incubation at 37°C for 24 h. The
extracted Evans blue was centrifuged, and the supernatant was collected and subjected to
measurement of absorbance at 632 nm. Evans blue solutions with different concentrations
was generated and measured at 632 nm to produce a standardized curve. The amount of Evans
Blue (µg) extravasated per g tissue was then calculated based on the
standardized curve.
TUNEL-NeuN double immunofluorescence staining
After 24 h of reperfusion, rats were sacrificed, and their brains were collected. The
brains were fixed in 10% formalin, embedded in paraffin, and cut into 5
µm slices. After paraffin removal with xylene and rehydration with
ethanol, the slices were permeabilized with 0.1% Triton X–100 (ST795, Beyotime, Shanghai,
China). Antigen retrieval was performed using citric acid-sodium citrate solution. The
sections were treated with 50 µl TUNEL solution (11684817910, Roche
Molecular Biochemicals, Mannheim, Germany; enzyme solution: label solution = 1:9). Next,
they were blocked with goat serum and then incubated with a primary antibody against NeuN
(ab104224, Abcam, Cambridge, UK; 1:300), followed by incubation with a FITC-labeled goat
anti-mouse IgG antibody (A0568, Beyotime; 1:200). The nuclei were stained with DAPI
(C1002, Beyotime). After sealing with anti-fade reagent, the slices were observed using a
fluorescent microscope (×400).
Double immunofluorescence staining
Sections were heated at 60°C for 2 h and then dewaxed and rehydrated. They were then
treated with antigen retrieval solution and blocked with goat serum. Primary antibodies
against Wnt5a (55184-1-AP, Proteintech; rabbit, 1:200) and NeuN (ab104224, Abcam; mouse,
1:300; combined and diluted with PBS) were added to the sections, and the sections were
then incubated overnight at 4°C. Subsequently, the sections were incubated with a
Cy3-labeled goat anti-rabbit IgG antibody (A0516, Beyotime) or FITC-labeled goat
anti-mouse IgG antibody (A0568, Beyotime; 1:200) for 90 min. The nuclei were stained with
DAPI (C1002, Beyotime). The cells from each of the different brain tissue sections were
visualized at 400× magnification with a microscope.
Analysis of luciferase activity
Wild-type Wnt5a 3’UTR was cloned downstream of the pmirGLO (E133A,
Promega, Madison, WI, USA) vector. Mutations were performed in the binding sites. The
pmirGLO vector plus miR-374 agomir or negative control agomir were transiently
co-transfected into 293T cells (Zhong Qiao Xin Zhou Biotechnology, Shanghai, China). The
activities of firefly and Renilla luciferases were measured with a dual-luciferase
reporter assay kit (KeyGen Biotech, Nanjing, China).
Statistical analysis
Statistical analysis was performed with the unpaired t-test or one-way
ANOVA followed by Dunnett’s multiple comparisons or Tukey’s multiple comparisons as
post-hoc tests. Data are presented as the mean ± SD deviation. P<0.05
was considered statistically significant (*P<0.05;
**P<0.01; ***P<0.001;
****P<0.0001).
Results
Cerebral IR caused neurological deficit, cerebral infarct, downregulation of miR-374,
and upregulation of Wnt5a
We first established a model of cerebral IR in male SD rats by reperfusion after MCAO.
There were obvious differences in neurobehavioral deficits and infarct volume in the IR
group compared with the sham group at 24 h after reperfusion (Figs. 1A–C). Next, effects of IR on the expression levels of miR-374 and Wnt5a were detected
by real-time PCR and Western blot analysis (Figs.
1D and E). miR-374 expression progressively decreased from 6 h to 72 h after
experimental cerebral IR in rats. On the other hand, the mRNA and protein expression
levels of Wnt5a progressively increased in the IR group. These data demonstrated that
cerebral IR altered the expression of miR-374 and Wnt5a in the rat brain.
Fig. 1.
Cerebral IR caused neurological deficit, cerebral infarct, downregulation of
miR-374, and upregulation of Wnt5a. (A) The neurobehavioral scores of animals
(evaluated 24 h after reperfusion). (B) Representative images of TTC-stained brain
sections of rats (evaluated 24 h after reperfusion). (C) Quantification of infarct
volume. (D) After 6 h, 24 h and 72 h of reperfusion, real-time PCR was performed to
assess the abundance of miR-374 and Wnt5a in the brain tissues of
rats. (E) After 6 h, 24 h and 72 h of reperfusion, the protein expression of WNT5A
was determined by Western blot analysis. Data are presented as the mean ± SD, and
they were analyzed by unpaired t-test or one-way ANOVA followed by Dunnett’s test.
Compared with the sham group: *P<0.05;
***P<0.001; ****P<0.0001.
Cerebral IR caused neurological deficit, cerebral infarct, downregulation of
miR-374, and upregulation of Wnt5a. (A) The neurobehavioral scores of animals
(evaluated 24 h after reperfusion). (B) Representative images of TTC-stained brain
sections of rats (evaluated 24 h after reperfusion). (C) Quantification of infarct
volume. (D) After 6 h, 24 h and 72 h of reperfusion, real-time PCR was performed to
assess the abundance of miR-374 and Wnt5a in the brain tissues of
rats. (E) After 6 h, 24 h and 72 h of reperfusion, the protein expression of WNT5A
was determined by Western blot analysis. Data are presented as the mean ± SD, and
they were analyzed by unpaired t-test or one-way ANOVA followed by Dunnett’s test.
Compared with the sham group: *P<0.05;
***P<0.001; ****P<0.0001.
Overexpression of miR-374 protected the brain from IR injury
We then investigated whether restoring the abundance of miR-374 by treating rats with
miR-374 agomir improved brain injury after IR. miR-374 agomir was first injected
intracerebrally 2 h before transient MCAO. After reperfusion for 24 h, real-time PCR was
performed, and the result showed that miR-374 agomir effectively increased miR-374
expression, which indicated that transfection was successful (Fig. 2A). After pretreatment with miR-374 agomir, MCAO, and then reperfusion,
neurobehavioral deficits were prominently improved (Fig. 2B). The infarct volume measured at 24 h of reperfusion was smaller in the
IR + miR-374 agomir group compared with the IR + NC agomir group (Figs. 2C and D). Similar results were observed when the brain water
content was measured in the ischemic hemispheres (Fig.
2E). Moreover, the measurement of Evans blue extravasation was performed to
evaluate the integrity of the BBB. The result data showed that cerebral IR caused
disruption of the BBB but that it was rescued by pretreatment with miR-374 agomir (Fig. 2F). Together, the above results implied that
miR-374 provided protection against cerebral IR injury.
Fig. 2.
Overexpression of miR-374 improved neurological deficit, cerebral infarct, cerebral
edema, and disruption of the BBB after IR. (A) The levels of miR-374 in brain
tissues of different groups. (B) Neurobehavioral scores of animals. (C)
Representative images of TTC staining. (D) Quantification of infarct volume. (E)
Quantification of the water content of the ischemic hemispheres. (F) Quantification
of Evans Blue extravasation in the brain. Data are presented as the mean ± SD, and
they were analyzed by unpaired t-test. Comparison of the sham group
with the IR group and the IR + NC agomir group with the IR + miR-374 agomir group:
**P<0.01; ***P<0.001;
****P<0.0001.
Overexpression of miR-374 improved neurological deficit, cerebral infarct, cerebral
edema, and disruption of the BBB after IR. (A) The levels of miR-374 in brain
tissues of different groups. (B) Neurobehavioral scores of animals. (C)
Representative images of TTC staining. (D) Quantification of infarct volume. (E)
Quantification of the water content of the ischemic hemispheres. (F) Quantification
of Evans Blue extravasation in the brain. Data are presented as the mean ± SD, and
they were analyzed by unpaired t-test. Comparison of the sham group
with the IR group and the IR + NC agomir group with the IR + miR-374 agomir group:
**P<0.01; ***P<0.001;
****P<0.0001.
Overexpression of miR-374 attenuated cerebral IR-induced apoptosis
To identify neuron apoptosis in brain injury induced by IR, double immunofluorescence
staining of TUNEL and NeuN, a marker for neurons, was employed in brain tissue. TUNEL
expression increased in neurons after cerebral IR. Pretreatment with miR-374 agomir
reduced the number of TUNEL-positive neurons (Fig.
3A). In addition, the Western blot results showed increased expression of BAX and
decreased expression of BCL-XL and BCL-2 in the IR group. However, the protein levels were
reversed by pretreatment with miR-374 agomir (Fig.
3B). These data suggested that miR-374 reduced neuron apoptosis after cerebral
IR.
Fig. 3.
Overexpression of miR-374 attenuated cerebral IR-induced apoptosis. (A)
Immunostaining showing differences in neuronal apoptosis among groups.
NeuN+/TUNEL+ colocalization is represented by arrows. Scale
bar, 50 µm. (B) Western blot showing expression of
apoptosis-related proteins (BCL-XL, BCL-2, and BAX) in brain tissues. Data are
presented as the mean ± SD, and they were analyzed by unpaired
t-test. Comparison of the sham group with the IR group and the IR +
NC agomir group with the IR + miR-374 agomir group: *P<0.05;
***P<0.001; ****P<0.0001.
Overexpression of miR-374 attenuated cerebral IR-induced apoptosis. (A)
Immunostaining showing differences in neuronal apoptosis among groups.
NeuN+/TUNEL+ colocalization is represented by arrows. Scale
bar, 50 µm. (B) Western blot showing expression of
apoptosis-related proteins (BCL-XL, BCL-2, and BAX) in brain tissues. Data are
presented as the mean ± SD, and they were analyzed by unpaired
t-test. Comparison of the sham group with the IR group and the IR +
NC agomir group with the IR + miR-374 agomir group: *P<0.05;
***P<0.001; ****P<0.0001.
miR-374 directly targeted and suppressed Wnt5a expression in cerebral IR rats
Since TargetScan and the Starbase database showed the directly binding of miR-374 and
Wnt5a, we first determined the level of Wnt5a after miR-374 agomir pretreatment and
cerebral IR by real-time PCR and Western blot. As shown in Figs. 4A and B, pretreatment with miR-374 agomir markedly attenuated the increase in Wnt5a level
compared with the IR group. Double immunofluorescence confirmed the above results and
further revealed the colocalization of Wnt5a with NeuN (Fig. 4C). Furthermore, the images also showed non-neuronal Wnt5a+
elements. Since previous studies demonstrated that Wnt5a is expressed in astrocytes in
brain tissues of rodents [26, 27], we deduced that these elements might be astrocytes. A dual
luciferase reporter assay was performed to validate the direct targeting of the
Wnt5a 3’-UTR by miR-374. The relative luciferase activity of the
Wnt5a wild-type 3’-UTR, but not the mutant 3’-UTR, was dramatically
suppressed by miR-374 agomir (Fig. 4D). These
results indicated that the effects of miR-374 in cerebral IR were associated with its
targeting of Wnt5a.
Fig. 4.
miR-374 directly targeted and suppressed Wnt5a expression in cerebral IR rats. Rats
were administrated with miR-374 agomir, and 24 h after cerebral IR, the expression
of Wnt5a in brain tissues was analyzed with real-time PCR (A) and Western blot (B).
(C) Representative immunofluorescence images showing colocalization of WNT5A in
neurons. NeuN+/ WNT5A+ colocalization is represented by
arrows. Scale bar, 50 µm. (D) The binding of miR-374 and Wnt5a was
assessed using a dual-luciferase reporter assay in 293T cells. WT: wild type. MT:
mutant type. Data in panels A, B, and D are shown as the mean ± SD from three
separate experiments, and comparisons were made with the unpaired
t-test for A and B and with one-way ANOVA followed by Tukey’s test
as the post-hoc test for D.
miR-374 directly targeted and suppressed Wnt5a expression in cerebral IRrats. Rats
were administrated with miR-374 agomir, and 24 h after cerebral IR, the expression
of Wnt5a in brain tissues was analyzed with real-time PCR (A) and Western blot (B).
(C) Representative immunofluorescence images showing colocalization of WNT5A in
neurons. NeuN+/ WNT5A+ colocalization is represented by
arrows. Scale bar, 50 µm. (D) The binding of miR-374 and Wnt5a was
assessed using a dual-luciferase reporter assay in 293T cells. WT: wild type. MT:
mutant type. Data in panels A, B, and D are shown as the mean ± SD from three
separate experiments, and comparisons were made with the unpaired
t-test for A and B and with one-way ANOVA followed by Tukey’s test
as the post-hoc test for D.
Discussion
During focal cerebral ischemia, if blood flow cannot be restored to the ischemic penumbra
or other measures cannot be taken, he focal cerebral ischemia often develops into infarction
that causes serious damage and may not be repairable. Reperfusion of the occluded vessels
immediately is the gold standard for treatment of acute ischemic stroke [28]. Nevertheless, reperfusion may still further damage
surrounding tissue by activating apoptosis and a neurodegenerative cascade [29]. At present, intravenous thrombolysis (rt-PA),
neuronal repair therapy, and neuroprotective agents are the possible therapeutic options for
ischemic stroke. However, the available treatments remain limited, and they have not yet
achieved satisfactory efficacy and safety [30,31,32]. In the
present research, we demonstrated that pretreatment with miR-374 agomir ameliorated brain
injury induced by IR, as evidenced by a decreased brain infarct volume, decreased water
content, improved neurobehavioral function and BBB disruption, and attenuated neuronal
apoptosis. We also found that these effects of miR-374 were dependent on its targeting of
Wnt5a. Our findings illuminated for the first time that miR-374 provides protection from
cerebral IR injury, suggesting a possible clinical role for miR-374 in ischemic stroke
treatment.In the rat models of cerebral IR injury, we found that the expression of miR-374
significantly decreased, which was not in agreement with the finding of Liu et
al. [10]. In their study, rats were
subjected to MCAO only without reperfusion, and miR-374 showed a compensatory increase and
exerted a protective effect after cerebral ischemia. In the rat model we established,
reperfusion following MCAO may have exacerbated the deleterious effects caused by ischemia,
thus leading to decreased miR-374 expression. Since miRNAs do not code for proteins, the
protective effect of miR-374 on cerebral IR injury is assumed to be exerted via the
regulation of its targets. A previous study showed that suppression of Wnt5a is
neuroprotective after cerebral ischemia [23]. In the
present study, in database predicted, we experimentally confirmed that
Wnt5a transcripts are targets of miR-374, which was predicted by
TargetScan and the Starbase database. Firstly, we observed a remarkable decrease in Wnt5a
expression in vivo after inducing overexpression of miR-374 with agomir.
Next, using the dual-luciferase assay, we substantiated the directly binding of miR-374 and
Wnt5a. Overall, our study indicated that miR-374 mitigated post-ischemic brain damage by
directly targeting to Wnt5a. Indeed, some other targets of miR-374 may also contribute to
protection of the brain from IR injury, and future studies will assess their relevance to
protection by knockdown of specific targets.In the central nervous system (CNS), Wnt5a plays a crucial role in the postsynaptic region
of central synapses. Wnt5a activates noncanonical Wnt signaling pathways, including
Wnt/Ca2+ and Wnt/JNK signaling pathways, and then increases the clustering of
PSD-95 and NMDAR [33, 34]. Furthermore, it regulates inhibitory synaptic transmission mediated by
GABAA receptors. As observed in hippocampal neurons, Wnt5a enhances the
recycling of functional GABAA receptors [33]. The above studies indicated that Wnt5a modulates the assembly and function of
the excitatory postsynaptic region of the brain. However, the role of Wnt5a in hippocampal
neurons damaged by brain IR is far from being elucidated. In this study, we provided
evidence for the role of Wnt5a in a rat model of cerebral IR. A limitation of the present
study was that we did not investigate Wnt5a-mediated neuroprotection with intracellular
experiments. Future work needs to be done to explore the protective effect of the
miR-374/Wnt5a pathway on hippocampal neuronal cells subjected to oxygen glucose deprivation
(OGD).Apoptosis is a common process that occurs in brain damage caused by IR [35, 36]. The
present study was undertaken to determine the effect of miR-374 on apoptosis. Our results
showed miR-374 protected neurons from apoptosis, as evidenced by fewer TUNEL-positive cells
in the brain tissue of the group pretreated with miR-374 agomir. The Bcl-2 family is a
family of regulators comprised of anti- and pro-apoptotic members that arbitrate cellular
life-or-death decisions. Bcl-2 and Bcl-xl, as anti-apoptotic members, prevent cells from
undergoing apoptosis. By contrast, Bax is a positive regulator that initiates apoptosis.
Both Bcl-2 and Bax regulate the release of cytochrome c or other apoptosis-inducing factors,
and hence caspase cascade activation, which leads to apoptosis [37]. In this study, we found miR-374 upregulated the expression of Bcl-xl
and Bcl-2 and downregulated Bax in brain tissues of cerebral IRrats. It has been proven
that both apoptosis and autophagy are activated in the ischemic penumbra [38], and a transition from apoptosis to autophagy might
occur in the subacute phase of stroke [39]. More
broadly, the effect of miR-374 on autophagy in cerebral IR injury could be assessed in
future research, which may yield further insight into the neuroprotective role of
miR-374.In conclusion, our study demonstrated that miR-374 improved brain injury and prevented
neuronal apoptosis in cerebral IRrats. Furthermore, miR-374 played a protective role in
cerebral IR injury by targeting Wnt5a. Taken together, identification of the miR-374/Wnt5a
axis may provide new insight into the potential molecular mechanisms of cerebral IR
injury.
Conflicts of Interests
The authors declare that they have no competing interests.
Authors’ Contributions
Fangyuan Xing conceived the study. Fangyuan Xing and Yongrong Liu carried out the
experiments. Ruifang Dong analyzed the data. Ye Cheng drafted the manuscript. Fangyuan Xing
revised the manuscript. All authors approved the final version of the manuscript.
Authors: Shadi Yaghi; Joshua Z Willey; Brett Cucchiara; Joshua N Goldstein; Nicole R Gonzales; Pooja Khatri; Louis J Kim; Stephan A Mayer; Kevin N Sheth; Lee H Schwamm Journal: Stroke Date: 2017-11-02 Impact factor: 7.914